Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Wyeth Scores Hat Trick In Biotech

February 12, 2007 | A version of this story appeared in Volume 85, Issue 7

Wyeth Pharmaceuticals has entered three collaborations with biotechnology companies. In one, Wyeth is collaborating with the Belgian firm Elbion on drugs for schizophrenia and other neurological disorders. The agreement includes up-front and milestone payments and research funding of up to a total of $110 million; Wyeth will also pay Elbion royalties on sales of products developed under the pact. In another venture, Wyeth will work with Nautilus Biotech, based in Paris, to develop recombinant Factor IX proteins for hemophilia B treatment. Also in the hemophilia field, Wyeth has entered a collaboration with San Diego-based MediVas, which will use its polymer-based drug delivery system to improve delivery methods for recombinant hemophilia products.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.